Session 4: Update on Psychopharmacotherapy and Therapeutic Neuromodulation

Egg Harbor, WI US
July 27, 2015 to July 31, 2015

This course will review the concepts of evidence-based and measurement-based care and use them to develop optimal treatment strategies for major psychiatric disorders.  Participants will recognize the significant number of patients who are insufficiently responsive to initial therapeutic interventions and will utilize available biological treatments optimally, including the first and second generation antipsychotics, antidepressants, mood stabilizing agents, anxiolytic/sedative hypnotics, and therapeutic neuromodulation.  Participants will also develop treatment strategies based on the results of randomized-controlled and pragmatic trials tempered by the realities of clinical practice and incorporate clinically relevant issues related to drug therapy including pharmacokinetics, pharmacodynamics, and drug interactions.

Monday Introduction; Treatment of high risk, prodromal, first-onset, early course, and multi-episode patients; Results from pilot studies of novel therapies, randomized controlled, and pragmatic trials

Tuesday Depressive disorders; Results of STAR*D and TADS trials with emphasis on their clinical relevance

Wednesday Mood and other psychiatric  disorders; Electroconvulsive therapy; Vagus nerve stimulation; Transcranial magnetic stimulation; Deep brain stimulation; Novel approaches such as optogenetics

Thursday Diagnosis and treatment of bipolar disorder; Results of STEP-BD trial; Diagnosis and drug therapy of dementia; Clinical implications of CATIE-Alzheimer’s trial results

Friday Diagnosis and drug therapy of anxiety-related and sleep disorders; Problems regarding patient adherence to treatment; Strategies to improve adherence

Accreditation and Designation of Credit:
The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Medical College of Wisconsin designates this live activity for a maximum of 15 AMA PRA Category 1 Creditstm. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The Medical College of Wisconsin designates this activity for up to 15 hours of participation for continuing education for allied health professionals.

The Medical College of Wisconsin is approved by the American Psychological Association to sponsor continuing education for psychologists. MCW maintains responsibility for this program and its content. This activity contains content or processes that may be potentially stressful.

The Medical College of Wisconsin is registered with the Illinois Department of Professional Regulation as a Continuing Education Sponsor for social workers (license number 159-000664).

Application for CME credit has been filed with the American Academy of Family Physicians. Determination of credit is pending.

Tuition includes course materials and continental breakfast.

Purchase an additional 5 DAY session and receive a $100.00 discount. Use coupon code: +DCSI

Please note: A $2.50 processing fee is assessed for all electronic registrations.

 

Target Audience

This advanced seminar is geared to mental health and health professionals.

Learning Objectives

(1) Appreciate the role of evidence-based and measurement-based care in the development and use of treatment strategies for major psychiatric disorders

(2) Consider the relative value of first and second generation antipsychotics in various stages of treatment for schizophrenia and related disorders

(3) Appreciate the emerging role of therapeutic neuromodulation in the treatment of psychiatric disorders

(4) Underscore the importance of developing strategies which enhance patient adherence to treatment


 

Additional information

CME Coordinator Contact Information

Name: 
Brenda Konczal
Phone Number: 
+1 (414) 955-7250
Course summary
Available credit: 
  • 15.00 AAFP
    AAFP credit.
  • 15.00 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 15.00 APA
    APA credit.
  • 15.00 Hours of Participation
    Hours of Participation credit.
  • 15.00 PA
    PA credit.
Course opens: 
03/09/2015
Course expires: 
12/31/2015
Event starts: 
07/27/2015 - 9:00am
Event ends: 
07/31/2015 - 12:15pm
Cost:
$2.50
The Landmark Resort and Conference Center
4929 Landmark Drive
Egg Harbor, WI 54209
United States

The Landmark Resort


4929 Landmark Drive
Egg Harbor, Wisconsin 54209
Reservations (800) 273-7877
E-mail: stay@thelandmarkresort.com
http//:www.thelandmarkresort.com

 
Philip Janicak, MD, is Consultant and Director of the Transcranial Magnetic Stimulation Center of Linden Oaks Medical Group in Naperville, IL.  He is a lecturer in the Department of Psychiatry at Northwestern University and was Professor of Psychiatry at Rush University prior to his current position.  He is a reviewer and editor of a number of psychiatric journals and is on the editorial boards of Directions in Psychiatry, Essential Psychopharmacology, and Psychiatric Annals.  Dr. Janicak’s awards and honors include Best Doctors in America, Outstanding Psychopharmacology Teacher at Rush University, Leading Health Professionals of the World, and he is a Distinguished Life Fellow of the American Psychiatric Association.

Disclosure:

Philip Janicak, MD
Research Support and Investigator for:
Otsuka Pharmaceuticals
Neurogenetics
Research Foundation for Mental Hygiene, Inc.

Available Credit

  • 15.00 AAFP
    AAFP credit.
  • 15.00 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 15.00 APA
    APA credit.
  • 15.00 Hours of Participation
    Hours of Participation credit.
  • 15.00 PA
    PA credit.

Accreditation Period

Course opens: 
03/09/2015
Course expires: 
12/31/2015

Price

Cost:
$2.50
Please login or register to take this course.